Ronald J Oudiz

Title(s)HS Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Cardiopulmonary Exercise Testing: Pulmonary Hypertension
    NIH K23RR017596Feb 1, 2003 - Jan 31, 2009
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells. EBioMedicine. 2024 Feb; 100:104900. Lewis MI, Shapiro S, Oudiz RJ, Nakamura M, Geft D, Matusov Y, Hage A, Tapson VF, Henry TD, Azizad P, Saggar R, Mirocha J, Karpov OA, Van Eyk JE, Marbán E. PMID: 38092579; PMCID: PMC10879003.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    2. Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil. Respir Med. 2023 11; 218:107374. Miller CE, Franco V, Smith JS, Balasubramanian V, Kingrey J, Zolty R, Melendres-Groves L, Huston J, Elwing JM, Ravichandran A, Cella D, Shen E, Seaman S, Thrasher CM, Broderick M, Oudiz RJ. PMID: 37532157.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil. Pulm Circ. 2023 Jul; 13(3):e12255. Kingrey JF, Miller CE, Franco V, Smith JS, Zolty R, Oudiz RJ, Elwing JM, Huston JH, Melendres-Groves L, Ravichandran A, Balasubramanian V, Wu B, Hwang S, Seaman S, Broderick M, Rahaghi FF. PMID: 37497167; PMCID: PMC10368085.
      View in: PubMed   Mentions: 1  
    4. Characteristics of patients with pulmonary arterial hypertension from an innovative, comprehensive real-world patient data repository. Pulm Circ. 2023 Jul; 13(3):e12258. Farber HW, Chakinala MM, Cho M, Frantz RP, Frick A, Lancaster L, Milligan S, Oudiz R, Panjabi S, Tsang Y, Nathan SD. PMID: 37427090; PMCID: PMC10326474.
      View in: PubMed   Mentions:
    5. The heart of the matter: Right heart imaging indicators for treatment escalation in pulmonary arterial hypertension. Pulm Circ. 2023 Apr; 13(2):e12240. Forfia P, Benza R, D'Alto M, De Marco T, Elwing JM, Frantz R, Haddad F, Oudiz R, Preston IR, Rosenkranz S, Ryan J, Schilz R, Shlobin OA, Vachiery JL, Vizza CD, Noordegraaf AV, Sketch MR, Broderick M, McLaughlin V. PMID: 37222992; PMCID: PMC10201108.
      View in: PubMed   Mentions:
    6. Using a knowledge translation program to facilitate guideline- and evidence-based patient management: the PAH-QuERI Extension Program. Pulm Circ. 2022 Jul; 12(3):e12134. McLaughlin VV, Channick RN, Lynum KSB, Oudiz RJ, Selej M, Tapson VF, Rubin LJ. PMID: 36172596; PMCID: PMC9469640.
      View in: PubMed   Mentions:
    7. Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension? Am J Respir Crit Care Med. 2022 04 01; 205(7):751-760. Vizza CD, Lang IM, Badagliacca R, Benza RL, Rosenkranz S, White RJ, Adir Y, Andreassen AK, Balasubramanian V, Bartolome S, Blanco I, Bourge RC, Carlsen J, Camacho REC, D'Alto M, Farber HW, Frantz RP, Ford HJ, Ghio S, Gomberg-Maitland M, Humbert M, Naeije R, Orfanos SE, Oudiz RJ, Perrone SV, Shlobin OA, Simon MA, Sitbon O, Torres F, Luc Vachiery J, Wang KY, Yacoub MH, Liu Y, Golden G, Matsubara H. PMID: 34905704.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    8. An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinil. Pulm Pharmacol Ther. 2021 02; 66:101979. Rahaghi FF, Allen RP, Balasubramanian VP, Chakinala MM, Elwing JM, Feldman J, Leary PJ, Rischard F, Safdar Z, Sood N, Oudiz RJ. PMID: 33259923.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Author rebuttal to response regarding "Letter to the Editor regarding 'Could pulmonary arterial hypertension patients be at lower risk from severe COVID-19?'". Pulm Circ. 2020 Jul-Sep; 10(3):2045894020936663. Horn E, Chakinala MM, Oudiz R, Joseloff E, Rosenzweig EB. PMID: 32637071; PMCID: PMC7313331.
      View in: PubMed   Mentions: 2  
    10. Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic. Pulm Circ. 2020 Apr-Jun; 10(2):2045894020920153. Ryan JJ, Melendres-Groves L, Zamanian RT, Oudiz RJ, Chakinala M, Rosenzweig EB, Gomberg-Maitland M. PMID: 32426111; PMCID: PMC7222260.
      View in: PubMed   Mentions: 33  
    11. Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19? Pulm Circ. 2020 Apr-Jun; 10(2):2045894020922799. Horn EM, Chakinala M, Oudiz R, Joseloff E, Rosenzweig EB. PMID: 32426113; PMCID: PMC7219006.
      View in: PubMed   Mentions: 33  
    12. Effects of oral sildenafil on exercise capacity in children with pulmonary arterial hypertension: a randomised trial. Open Heart. 2019; 6(2):e001149. Russell S, Beghetti M, Oudiz R, Balagtas C, Zhang M, Ivy D. PMID: 31908813; PMCID: PMC6927510.
      View in: PubMed   Mentions: 1     Fields:    
    13. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. J Heart Lung Transplant. 2019 12; 38(12):1286-1295. McLaughlin VV, Vachiery JL, Oudiz RJ, Rosenkranz S, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rubin LJ, Blair C, Langley J, Hoeper MM, AMBITION Study Group. PMID: 31648845.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    14. Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. Respir Res. 2019 Sep 12; 20(1):208. White RJ, Vonk-Noordegraaf A, Rosenkranz S, Oudiz RJ, McLaughlin VV, Hoeper MM, Grünig E, Ghofrani HA, Chakinala MM, Barberà JA, Blair C, Langley J, Frost AE. PMID: 31511080; PMCID: PMC6739949.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    15. Diagnosis of pulmonary hypertension. Eur Respir J. 2019 01; 53(1). Frost A, Badesch D, Gibbs JSR, Gopalan D, Khanna D, Manes A, Oudiz R, Satoh T, Torres F, Torbicki A. PMID: 30545972; PMCID: PMC6351333.
      View in: PubMed   Mentions: 154     Fields:    Translation:Humans
    16. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respir Med. 2019 03; 7(3):227-238. Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR, UK NIHR BioResource Rare Diseases Consortium, UK PAH Cohort Study Consortium, US PAH Biobank Consortium. PMID: 30527956; PMCID: PMC6391516.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCells
    17. Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. Semin Arthritis Rheum. 2019 06; 48(6):1059-1067. Young A, Nagaraja V, Basilious M, Habib M, Townsend W, Gladue H, Badesch D, Gibbs JSR, Gopalan D, Manes A, Oudiz R, Satoh T, Torbicki A, Torres F, McLaughlin V, Khanna D. PMID: 30415942; PMCID: PMC7155785.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansPHPublic Health
    18. Association between Pulmonary Hypertension and Clinical Outcomes in Hospitalized Patients with Sickle Cell Disease. Am J Respir Crit Care Med. 2018 08 15; 198(4):534-537. Agarwal MA, Shah M, Patel B, Nolan VG, Reed GL, Oudiz RJ, Choudhary G, Maron BA. PMID: 29648884; PMCID: PMC6118030.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). Respir Med. 2017 05; 126:84-92. Shapiro S, Torres F, Feldman J, Keogh A, Allard M, Blair C, Gillies H, Tislow J, Oudiz RJ. PMID: 28427554.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    20. An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertension. Pulm Circ. 2016 Dec; 6(4):532-538. Oudiz R, Agarwal M, Rischard F, De Marco T. PMID: 28090295; PMCID: PMC5210049.
      View in: PubMed   Mentions: 1  
    21. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med. 2016 11; 4(11):894-901. Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin LJ, Vachiery JL. PMID: 27745818.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    22. Pulmonary Hypertension. Cardiol Clin. 2016 Aug; 34(3):ix. Oudiz RJ. PMID: 27443144.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Classification of Pulmonary Hypertension. Cardiol Clin. 2016 Aug; 34(3):359-61. Oudiz RJ. PMID: 27443133.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    24. Phase I safety study of ranolazine in pulmonary arterial hypertension. Pulm Circ. 2015 Dec; 5(4):691-700. Gomberg-Maitland M, Schilz R, Mediratta A, Addetia K, Coslet S, Thomeas V, Gillies H, Oudiz RJ. PMID: 26697176; PMCID: PMC4671743.
      View in: PubMed   Mentions: 16  
    25. The Assessment of the Right Heart Failure Syndrome. Semin Respir Crit Care Med. 2015 Dec; 36(6):934-42. Kholdani CA, Oudiz RJ, Fares WH. PMID: 26595052.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    26. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27; 373(9):834-44. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ, AMBITION Investigators. PMID: 26308684.
      View in: PubMed   Mentions: 402     Fields:    Translation:Humans
    27. [Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology]. Turk Kardiyol Dern Ars. 2014 Oct; 42 Suppl 1:29-44. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM. PMID: 25697032.
      View in: PubMed   Mentions:    Fields:    
    28. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study. J Cardiovasc Pharmacol Ther. 2014 Nov; 19(6):550-7. Frantz RP, Durst L, Burger CD, Oudiz RJ, Bourge RC, Franco V, Waxman AB, McDevitt S, Walker S. PMID: 24742768.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    29. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl):D22-33. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM. PMID: 24355638.
      View in: PubMed   Mentions: 339     Fields:    Translation:HumansAnimals
    30. Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases. Circulation. 2013 Sep 24; 128(13):1470-9. Lewis GD, Bossone E, Naeije R, Grünig E, Saggar R, Lancellotti P, Ghio S, Varga J, Rajagopalan S, Oudiz R, Rubenfire M. PMID: 24060943.
      View in: PubMed   Mentions: 126     Fields:    Translation:HumansAnimals
    31. Updating clinical endpoints in pulmonary arterial hypertension: when challenges are welcome. Pulm Circ. 2013 Sep; 3(3):721-2. Hassoun PM, Nikkho S, Oudiz RJ. PMID: 24618557; PMCID: PMC4070818.
      View in: PubMed   Mentions: 1  
    32. Death in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013 Aug 01; 188(3):269-70. Oudiz RJ. PMID: 23905521.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    33. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013 Jul 30; 128(5):502-11. Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, Oudiz RJ, Boateng F, Scalise AV, Roessig L, Semigran MJ, Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT). PMID: 23775260.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCTClinical Trials
    34. Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. Chest. 2013 Feb 01; 143(2):324-332. McLaughlin VV, Langer A, Tan M, Clements PJ, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Pulmonary Arterial Hypertension-Quality Enhancement Research Initiative (PAH-QuERI) Investigators. PMID: 22910999.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    35. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest. 2013 Feb 01; 143(2):315-323. Fritz JS, Blair C, Oudiz RJ, Dufton C, Olschewski H, Despain D, Gillies H, Kawut SM. PMID: 22814814; PMCID: PMC4694187.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    36. Updating clinical endpoint definitions. Pulm Circ. 2013 Jan; 3(1):206-16. Hassoun PM, Nikkho S, Rosenzweig EB, Moreschi G, Lawrence J, Teeter J, Meier C, Ghofrani AH, Minai O, Rinaldi P, Michelakis E, Oudiz RJ. PMID: 23662199; PMCID: PMC3641732.
      View in: PubMed   Mentions: 13  
    37. Cardiopulmonary exercise testing. Pulm Med. 2012; 2012:564134. Howard L, Grocott MP, Naeije R, Oudiz R, Wensel R. PMID: 23365737; PMCID: PMC3556852.
      View in: PubMed   Mentions:    Fields:    
    38. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012 Aug 21; 60(8):768-74. Oudiz RJ, Brundage BH, Galiè N, Ghofrani HA, Simonneau G, Botros FT, Chan M, Beardsworth A, Barst RJ, PHIRST Study Group. PMID: 22818063.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    39. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. Eur J Heart Fail. 2012 Aug; 14(8):946-53. Ghio S, Bonderman D, Felix SB, Ghofrani HA, Michelakis ED, Mitrovic V, Oudiz RJ, Frey R, Roessig L, Semigran MJ. PMID: 22719060.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    40. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis. 2012 Feb; 71(2):249-52. Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A, Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators. PMID: 21998119.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    41. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther. 2012 Apr; 30(2):93-9. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ, ARIES-3 Study Group. PMID: 21884013.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    42. Quality indicator set for systemic sclerosis. Clin Exp Rheumatol. 2011 Mar-Apr; 29(2 Suppl 65):S33-9. Khanna D, Kowal-Bielecka O, Khanna PP, Lapinska A, Asch SM, Wenger N, Brown KK, Clements PJ, Getzug T, Mayes MD, Medsger TA, Oudiz R, Simms R, Steen V, Maranian P, Furst DE. PMID: 21586216; PMCID: PMC3887520.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    43. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. Am J Cardiol. 2011 Jul 15; 108(2):302-7. Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C. PMID: 21545989.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    44. Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol. 2011 Mar 01; 57(9):1053-61. Gomberg-Maitland M, Dufton C, Oudiz RJ, Benza RL. PMID: 21349396.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    45. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2011 Jun; 30(6):632-43. Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, Sundin DP, Galiè N, Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. PMID: 21256048.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    46. Developing pulmonary vasculopathy in systemic sclerosis, detected with non-invasive cardiopulmonary exercise testing. PLoS One. 2010 Dec 13; 5(12):e14293. Dumitrescu D, Oudiz RJ, Karpouzas G, Hovanesyan A, Jayasinghe A, Hansen JE, Rosenkranz S, Wasserman K. PMID: 21179195; PMCID: PMC3001444.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    47. Usefulness of right-to-left shunting and poor exercise gas exchange for predicting prognosis in patients with pulmonary arterial hypertension. Am J Cardiol. 2010 Apr 15; 105(8):1186-91. Oudiz RJ, Midde R, Hovenesyan A, Sun XG, Roveran G, Hansen JE, Wasserman K. PMID: 20381675; PMCID: PMC3031421.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    48. Exercise training in patients with pulmonary arterial hypertension: a case report. Cardiopulm Phys Ther J. 2009 Dec; 20(4):12-8. Shoemaker MJ, Wilt JL, Dasgupta R, Oudiz RJ. PMID: 20467524; PMCID: PMC2845256.
      View in: PubMed   Mentions: 16  
    49. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Nov 17; 54(21):1971-81. Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ, ARIES Study Group. PMID: 19909879.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    50. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30; 54(1 Suppl):S55-S66. Badesch DB, Champion HC, Gomez Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A. PMID: 19555859.
      View in: PubMed   Mentions: 351     Fields:    Translation:Humans
    51. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30; 54(1 Suppl):S97-S107. McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, Gibbs JSR, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W. PMID: 19555863.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    52. Successful tricuspid valve replacement in a patient with severe pulmonary arterial hypertension and preserved right ventricular systolic function. Case Rep Med. 2009; 2009:108295. Aboulhosn JA, Oudiz RJ, Dave AS, Ardehali A, Ross DJ. PMID: 19707472; PMCID: PMC2729471.
      View in: PubMed   Mentions:
    53. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009 Jun 09; 119(22):2894-903. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ, Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. PMID: 19470885.
      View in: PubMed   Mentions: 335     Fields:    Translation:Humans
    54. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr; 157(4):625-35. Oudiz RJ, Farber HW. PMID: 19332188.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    55. Exercise-induced pulmonary arterial hypertension: a new addition to the spectrum of pulmonary vascular diseases. Circulation. 2008 Nov 18; 118(21):2120-1. Oudiz RJ, Rubin LJ. PMID: 19015412.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    56. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009 Jan; 135(1):122-129. McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ. PMID: 18812445.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    57. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10; 117(23):3010-9. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multic. PMID: 18506008.
      View in: PubMed   Mentions: 328     Fields:    Translation:Humans
    58. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. J Clin Pharmacol. 2008 Jan; 48(1):19-25. McSwain CS, Benza R, Shapiro S, Hill N, Schilz R, Elliott CG, Zwicke DL, Oudiz RJ, Staszewski JP, Arneson CP, Wade M, Zaccardelli D, McLaughlin V. PMID: 18094217.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    59. Serial hemodynamics and complications of pregnancy in severe pulmonary arterial hypertension. Cardiology. 2008; 109(4):237-40. Nahapetian A, Oudiz RJ. PMID: 17873487.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    60. Effect of sildenafil on ventilatory efficiency and exercise tolerance in pulmonary hypertension. Eur J Heart Fail. 2007 Sep; 9(9):917-21. Oudiz RJ, Roveran G, Hansen JE, Sun XG, Wasserman K. PMID: 17707133; PMCID: PMC2071948.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    61. Prevalence of obstructive coronary artery disease in an outpatient cardiac CT angiography environment. Int J Cardiol. 2008 Sep 16; 129(1):32-6. Budoff MJ, Gopal A, Gul KM, Mao SS, Fischer H, Oudiz RJ. PMID: 17651836.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    62. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis. 2007 Nov; 66(11):1467-72. Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, Oudiz RJ, Robbins IM, Seibold JR, Shapiro S, Tapson VF, Barst RJ. PMID: 17472992; PMCID: PMC2111639.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    63. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med. 2007 Mar; 28(1):233-41, x. Oudiz RJ. PMID: 17338938.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    64. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant. 2007 Jan; 26(1):63-9. Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ. PMID: 17234519.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    65. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006 Dec 19; 48(12):2546-52. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, Barst RJ, Ghofrani HA, Jing ZC, Opitz C, Seyfarth HJ, Halank M, McLaughlin V, Oudiz RJ, Ewert R, Wilkens H, Kluge S, Bremer HC, Baroke E, Rubin LJ. PMID: 17174196.
      View in: PubMed   Mentions: 152     Fields:    Translation:Humans
    66. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J. 2006 Sep; 152(3):521-6. Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz RJ, Robbins IM, Tapson V, Abenhaim L, Constantine G. PMID: 16923424.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    67. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006 Dec 01; 174(11):1257-63. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. PMID: 16946127.
      View in: PubMed   Mentions: 145     Fields:    Translation:Humans
    68. Noninvasive gadolinium-enhanced three dimensional computed tomography coronary angiography. Acad Radiol. 2006 Jul; 13(7):840-9. Gul KM, Mao SS, Gao Y, Oudiz RJ, Rasouli ML, Gopal A, Budoff MJ. PMID: 16777558.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    69. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol. 2006 Jan 01; 97(1):123-6. Oudiz RJ, Barst RJ, Hansen JE, Sun XG, Garofano R, Wu X, Wasserman K. PMID: 16377296.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    70. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005 Aug 02; 46(3):529-35. Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. PMID: 16053970.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCTClinical Trials
    71. The role of exercise testing in the management of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2005 Aug; 26(4):379-84. Oudiz RJ. PMID: 16121314.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    72. Coronary venous imaging with electron beam computed tomographic angiography: three-dimensional mapping and relationship with coronary arteries. Am Heart J. 2005 Aug; 150(2):315-22. Mao S, Shinbane JS, Girsky MJ, Child J, Carson S, Oudiz RJ, Budoff MJ. PMID: 16086937.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    73. Detection of small vessels with electron beam computed tomographic angiography using 1.5 and 3 mm collimator protocols. Int J Cardiovasc Imaging. 2006 Apr; 22(2):275-82. Mao S, Shinbane JS, Oudiz RJ, Flores F, Chau A, Liu S, Wang S, Gao Y, Budoff MJ. PMID: 16041563.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    74. End-tidal PCO2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Chest. 2005 May; 127(5):1637-46. Yasunobu Y, Oudiz RJ, Sun XG, Hansen JE, Wasserman K. PMID: 15888840.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    75. Comparison of coronary artery calcium screening image quality between C-150 and e-Speed electron beam scanners. Acad Radiol. 2005 Mar; 12(3):309-12. Budoff MJ, Shinbane JS, Oudiz RJ, Child J, Carson S, Chau A, Tseng P, Gao Y, Mao S. PMID: 15766691.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    76. Clinical efficacy of sildenafil in primary pulmonary hypertension. J Am Coll Cardiol. 2004 Dec 07; 44(11):2256; author reply 2256-7. Oudiz RJ, Wasserman K. PMID: 15582332.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    77. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004 Aug; 126(2):420-7. Oudiz RJ, Schilz RJ, Barst RJ, Galié N, Rich S, Rubin LJ, Simonneau G, Treprostinil Study Group. PMID: 15302727.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCTClinical Trials
    78. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest. 2004 Jul; 126(1):90-4. Oudiz RJ, Widlitz A, Beckmann XJ, Camanga D, Alfie J, Brundage BH, Barst RJ. PMID: 15249447.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsPHPublic Health
    79. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):48S-55S. Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, Torbicki A. PMID: 15194178.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    80. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004 Feb 15; 169(4):441-7. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR, STRIDE-1 Study Group. PMID: 14630619.
      View in: PubMed   Mentions: 144     Fields:    Translation:HumansCTClinical Trials
    81. Comparison of LV mass and volume measurements derived from electron beam tomography using cine imaging and angiographic imaging. Int J Cardiovasc Imaging. 2003 Oct; 19(5):439-45. Mao S, Takasu J, Child J, Carson S, Oudiz R, Budoff MJ. PMID: 14609196.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    82. Pulmonary artery systolic pressure estimated by echocardiogram vs catheterization in patients awaiting lung transplantation. J Heart Lung Transplant. 2003 Jul; 22(7):832-3; author reply 833. Oudiz RJ, Ginzton L. PMID: 12873560.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    83. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Jun 18; 41(12):2119-25. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R, Beraprost Study Group. PMID: 12821234.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansCTClinical Trials
    84. Measurement of the RT interval on ECG records during electron-beam CT. Acad Radiol. 2003 Jun; 10(6):638-43. Mao S, Lu B, Takasu J, Oudiz RJ, Budoff MJ. PMID: 12809417.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    85. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol. 2003 Mar 19; 41(6):1028-35. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. PMID: 12651053.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    86. Sensitivity to detect small coronary artery calcium lesions with varying slice thickness using electron beam tomography. Invest Radiol. 2003 Mar; 38(3):183-7. Mao S, Child J, Carson S, Liu SC, Oudiz RJ, Budoff MJ. PMID: 12595800.
      View in: PubMed   Mentions: 7     Fields:    
    87. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003 Feb; 41(2):293-9. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S, Treprostinil Study Group. PMID: 12548091.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    88. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J. 2002 May; 143(5):E4. Langleben D, Christman BW, Barst RJ, Dias VC, Galiè N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB, Levy RD, Mehta S, Seeger W, Solèr M. PMID: 12040360.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    89. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 Mar 15; 165(6):800-4. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ, Treprostinil Study Group. PMID: 11897647.
      View in: PubMed   Mentions: 326     Fields:    Translation:HumansCTClinical Trials
    90. Gas exchange detection of exercise-induced right-to-left shunt in patients with primary pulmonary hypertension. Circulation. 2002 Jan 01; 105(1):54-60. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. PMID: 11772876.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    91. Secondary Pulmonary Hypertension. Curr Treat Options Cardiovasc Med. 2001 Apr; 3(2):115-124. Oudiz RJ. PMID: 11242558.
      View in: PubMed   Mentions: 1  
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Ronald's Networks
    Concepts (257)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (12)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California